Artivion vs Bioventus
Bioventus is the larger business, with $568m of revenue in fiscal 2025 against $441m for Artivion (1.3 times as much). Artivion grew faster (13.6% against -0.9%). Bioventus kept more of each dollar of sales as profit: a net margin of 4.0% against 2.2%. Artivion carries less debt relative to equity (49.1% against 159.7%).
| Latest fiscal year | ArtivionAORT, 2025 | BioventusBVS, 2025 |
|---|---|---|
| Revenue | $441m | $568m |
| Revenue growth | 13.6% | -0.9% |
| Net income | $9.8m | $22.7m |
| Operating margin | 7.6% | 9.5% |
| Net margin | 2.2% | 4.0% |
| Return on equity | 2.7% | 13.7% |
| Free cash flow | $839,000 | $72.1m |
| Cash | $64.9m | $51.2m |
| Total debt | $220m | $294m |
| Debt to equity | 49.1% | 159.7% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 1,800 | 930 |
| Market value | $1.15bn | $795m |
| Price vs our value range | — | Within our value range |
| Moat score | 39 (Weak) | 43 (Weak) |
| Insider trades, 12 months | 0 buys, 64 sales | 0 buys, 3 sales |